Valneva SE

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

08 9 2022 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

06 9 2022 01:00:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: August 31, 2022

05 9 2022 12:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

29 8 2022 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

23 8 2022 11:45:00 提供 Nasdaq GlobeNewswire

Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

18 8 2022 12:00:00 提供 Nasdaq GlobeNewswire

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

18 8 2022 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

15 8 2022 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports H1 2022 Results and Provides Corporate Updates

11 8 2022 01:00:00 提供 Nasdaq GlobeNewswire

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

08 8 2022 16:45:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - July 31, 2022

04 8 2022 12:00:00 提供 Nasdaq GlobeNewswire

Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine

01 8 2022 11:45:00 提供 Nasdaq GlobeNewswire

European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine

20 7 2022 12:00:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - June 30, 2022

05 7 2022 12:00:00 提供 Nasdaq GlobeNewswire

Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022

27 6 2022 02:30:00 提供 Nasdaq GlobeNewswire

Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

24 6 2022 12:00:00 提供 Nasdaq GlobeNewswire

Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

24 6 2022 01:05:00 提供 Nasdaq GlobeNewswire

Valneva and Pfizer Announce Closing of Equity Investment

23 6 2022 11:45:00 提供 Nasdaq GlobeNewswire

Valneva announces resumption of trading of its ordinary shares on Euronext Paris

23 6 2022 10:00:00 提供 Nasdaq GlobeNewswire

Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe

23 6 2022 09:16:12 提供 Nasdaq GlobeNewswire